- Centre for Cancer Research - Research Publications
Centre for Cancer Research - Research Publications
Permanent URI for this collection
141 results
Filters
Reset filtersSettings
Statistics
Citations
Search Results
Now showing
1 - 10 of 141
-
ItemTargeting Menin disrupts the KMT2A/B and polycomb balance to paradoxically activate bivalent genesSparbier, CE ; Gillespie, A ; Gomez, J ; Kumari, N ; Motazedian, A ; Chan, KL ; Bell, CC ; Gilan, O ; Chan, Y-C ; Popp, S ; Gough, DJ ; Eckersley-Maslin, MA ; Dawson, S-J ; Lehner, PJ ; Sutherland, KD ; Ernst, P ; McGeehan, GM ; Lam, EYN ; Burr, ML ; Dawson, MA (NATURE PORTFOLIO, 2023-01-12)Precise control of activating H3K4me3 and repressive H3K27me3 histone modifications at bivalent promoters is essential for normal development and frequently corrupted in cancer. By coupling a cell surface readout of bivalent MHC class I gene expression with whole-genome CRISPR-Cas9 screens, we identify specific roles for MTF2-PRC2.1, PCGF1-PRC1.1 and Menin-KMT2A/B complexes in maintaining bivalency. Genetic loss or pharmacological inhibition of Menin unexpectedly phenocopies the effects of polycomb disruption, resulting in derepression of bivalent genes in both cancer cells and pluripotent stem cells. While Menin and KMT2A/B contribute to H3K4me3 at active genes, a separate Menin-independent function of KMT2A/B maintains H3K4me3 and opposes polycomb-mediated repression at bivalent genes. Release of KMT2A from active genes following Menin targeting alters the balance of polycomb and KMT2A at bivalent genes, facilitating gene activation. This functional partitioning of Menin-KMT2A/B complex components reveals therapeutic opportunities that can be leveraged through inhibition of Menin.
-
ItemDescription of a novel subtype of acute myeloid leukemia defined by recurrent CBFB insertions.Ryland, GL ; Umeda, M ; Holmfeldt, L ; Lehmann, S ; Herlin, MK ; Ma, J ; Khanlari, M ; Rubnitz, JE ; Ries, RE ; Kosasih, HJ ; Ekert, PG ; Goh, HN ; Tiong, IS ; Grimmond, SM ; Haferlach, C ; Day, RB ; Ley, TJ ; Meshinchi, S ; Ma, X ; Blombery, P ; Klco, JM (American Society of Hematology, 2023-02-16)
-
ItemNo Preview AvailableAcquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemiaMoujalled, DM ; Brown, FC ; Chua, CC ; Dengler, MA ; Pomilio, G ; Anstee, NS ; Litalien, V ; Thompson, E ; Morley, T ; MacRaild, S ; Tiong, IS ; Morris, R ; Dun, K ; Zordan, A ; Shah, J ; Banquet, S ; Halilovic, E ; Morris, E ; Herold, MJ ; Lessene, G ; Adams, JM ; Huang, DCS ; Roberts, AW ; Blombery, P ; Wei, AH (AMER SOC HEMATOLOGY, 2023-02-09)Randomized trials in acute myeloid leukemia (AML) have demonstrated improved survival by the BCL-2 inhibitor venetoclax combined with azacitidine in older patients, and clinical trials are actively exploring the role of venetoclax in combination with intensive chemotherapy in fitter patients with AML. As most patients still develop recurrent disease, improved understanding of relapse mechanisms is needed. We find that 17% of patients relapsing after venetoclax-based therapy for AML have acquired inactivating missense or frameshift/nonsense mutations in the apoptosis effector gene BAX. In contrast, such variants were rare after genotoxic chemotherapy. BAX variants arose within either leukemic or preleukemic compartments, with multiple mutations observed in some patients. In vitro, AML cells with mutated BAX were competitively selected during prolonged exposure to BCL-2 antagonists. In model systems, AML cells rendered deficient for BAX, but not its close relative BAK, displayed resistance to BCL-2 targeting, whereas sensitivity to conventional chemotherapy was variable. Acquired mutations in BAX during venetoclax-based therapy represent a novel mechanism of resistance to BH3-mimetics and a potential barrier to the long-term efficacy of drugs targeting BCL-2 in AML.
-
ItemEnrichment of BTK Leu528Trp mutations in patients with CLL on zanubrutinib: potential for pirtobrutinib cross-resistanceBlombery, P ; Thompson, ER ; Lew, TE ; Tiong, IS ; Bennett, R ; Cheah, CY ; Lewis, KL ; Handunnetti, SM ; Tang, CPS ; Roberts, A ; Seymour, JF ; Tam, CS (ELSEVIER, 2022-10-21)The covalent Bruton's tyrosine kinase inhibitors (BTKis) are highly effective for the treatment of chronic lymphocytic leukemia (CLL). The dominant resistance mechanism observed with the BTKi ibrutinib is the development of BTK Cys481 codon mutations. Whether a similar resistance mutation profile exists for the newer-generation, more selective BTKi zanubrutinib is unknown. In samples referred for diagnostic next-generation sequencing in patients with progressive CLL, we observed an enrichment in the kinase-dead BTK Leu528Trp mutation in patients treated with zanubrutinib compared with ibrutinib (54%; 7 of 13 vs 4%; 1 of 24, P = .001). We describe 2 patients with BTK Leu528Trp mutations who showed clinical cross-resistance and progressive enrichment of the BTK Leu528Trp mutation over time when treated with the noncovalent BTKi pirtobrutinib. Both patients subsequently responded to venetoclax-based treatment. In summary, we have identified an enrichment of the BTK Leu528Trp mutation arising in patients treated with zanubrutinib that may impart cross-resistance to the noncovalent inhibitor pirtobrutinib and therefore may have implications for sequencing of these treatments in CLL.
-
ItemClinical implications of prospective genomic profiling of metastatic breast cancer patients (vol 22, 91, 2020)van Geelen, CT ; Savas, P ; Teo, ZL ; Luen, SJ ; Weng, C-F ; Ko, Y-A ; Kuykhoven, KS ; Caramia, F ; Salgado, R ; Francis, PA ; Dawson, S-J ; Fox, SB ; Fellowes, A ; Loi, S (BMC, 2022-07-15)
-
ItemComprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesotheliomaCreaney, J ; Patch, A-M ; Addala, V ; Sneddon, SA ; Nones, K ; Dick, IM ; Lee, YCG ; Newell, F ; Rouse, EJ ; Naeini, MM ; Kondrashova, O ; Lakis, V ; Nakas, A ; Waller, D ; Sharkey, A ; Mukhopadhyay, P ; Kazakoff, SH ; Koufariotis, LT ; Davidson, AL ; Ramarao-Milne, P ; Holmes, O ; Xu, Q ; Leonard, C ; Wood, S ; Grimmond, SM ; Bueno, R ; Fennell, DA ; Pearson, J ; Robinson, BW ; Waddell, N (BMC, 2022-05-30)BACKGROUND: Malignant pleural mesothelioma (MPM) has a poor overall survival with few treatment options. Whole genome sequencing (WGS) combined with the immune features of MPM offers the prospect of identifying changes that could inform future clinical trials. METHODS: We analysed somatic mutations from 229 MPM samples, including previously published data and 58 samples that had undergone WGS within this study. This was combined with RNA-seq analysis to characterize the tumour immune environment. RESULTS: The comprehensive genome analysis identified 12 driver genes, including new candidate genes. Whole genome doubling was a frequent event that correlated with shorter survival. Mutational signature analysis revealed SBS5/40 were dominant in 93% of samples, and defects in homologous recombination repair were infrequent in our cohort. The tumour immune environment contained high M2 macrophage infiltrate linked with MMP2, MMP14, TGFB1 and CCL2 expression, representing an immune suppressive environment. The expression of TGFB1 was associated with overall survival. A small subset of samples (less than 10%) had a higher proportion of CD8 T cells and a high cytolytic score, suggesting a 'hot' immune environment independent of the somatic mutations. CONCLUSIONS: We propose accounting for genomic and immune microenvironment status may influence therapeutic planning in the future.
-
ItemNo Preview AvailableTrajectories of glycemic control with clinical pharmacy specialist management of veterans with type 2 diabetes.Grabarczyk, TR ; Roberts, AW ; Mahnken, JD ; Grauer, D (Elsevier BV, 2022-06)BACKGROUND: Improved control of glycemic control likely lowers the risk of diabetes complications and clinical pharmacy specialist (CPS) services can improve glycemic control. Though the pattern of control may also matter in terms of outcomes. OBJECTIVES: The objective of this study was to examine the longitudinal trajectories of HbA1c among a large population of Veterans with type 2 diabetes who received CPS-led diabetes management. METHODS: This is an observational, multicenter cohort study of Veterans with type-2 diabetes managed by CPSs between 7/1/2013 and 7/1/2017 with baseline glycosylated hemoglobin (HbA1c) level ≥8%. Two years of HbA1c measurements were used to group patients into distinct patterns of HbA1c trajectories over time using group-based trajectory modeling. Characteristics associated with successful HbA1c trajectories and association of assigned trajectories with all-cause and diabetes-related hospitalizations were analyzed using logistic regression. RESULTS: A total of 4119 Veterans were included and able to be successfully segmented into six distinct HbA1c trajectory groups over time: High Gradually Decreasing (n = 325, 7.9%), Moderate Early Decline (n = 1692, 41.1%), Large Early Decline (n = 231, 5.6%), Uncontrolled Stable (n = 1468, 35.6%), Early Decline/Subsequent Increase (n = 266, 6.5%), and Very Uncontrolled Stable (n = 137, 3.3%). The distinguishing factor between successful and less successful trajectories appears to be the progress made within the first six months of pharmacist management. CONCLUSIONS: Significant variability exists in the pattern of glycemic control over time of type 2 diabetes patients managed by clinical pharmacy specialists. Limited resources should be first prioritized to managing patients with very elevated HbA1c and into the first six months of CPS management.
-
ItemPotential Clinical Utility of a Targeted Circulating Tumor DNA Assay in Esophageal AdenocarcinomaCabalag, CS ; Yates, M ; Corrales, MB ; Yeh, P ; Wong, SQ ; Zhang, BZ ; Fujihara, KM ; Chong, L ; Hii, MW ; Dawson, S-J ; Phillips, WA ; Duong, CP ; Clemons, NJ (LIPPINCOTT WILLIAMS & WILKINS, 2022-08-01)OBJECTIVE: To explore the clinical utility of circulating tumor DNA (ctDNA) in esophageal adenocarcinoma (EAC) by developing a cost-effective and rapid technique utilising targeted amplicon sequencing. SUMMARY OF BACKGROUND DATA: Emerging evidence suggests that levels of ctDNA in the blood can be used to monitor treatment response and in the detection of disease recurrence in various cancer types. Current staging modalities for EAC such as computerised tomography of the chest/abdomen/pelvis (CT) and positron emission tomography (PET) do not reliably detect occult micro-metastatic disease, the presence of which signifies a poor prognosis. After curative-intent treatment, some patients are still at high risk of recurrent disease, and there is no widely accepted optimal surveillance tool for patients with EAC. METHODS: Sixty-two patients with EAC were investigated for the presence of ctDNA using a tumor-informed approach. We designed a custom targeted amplicon sequencing panel of target specific primers covering mutational foci in 9 of the most commonly mutated genes in EAC. Serial blood samples were taken before and after neoadjuvant treatment (NAT), and during surveillance. RESULTS: Somatic mutations were detected in pre-treatment biopsy samples of 55 out of 62 (89%) EAC patients. Mutations in TP53 (80%) were the most common. Out of these 55 patients, 20 (36%) had detectable ctDNA at baseline. The majority (90%) of patients with detectable ctDNA had either locally advanced tumors, nodal involvement or metastatic disease. In patients with locally advanced tumors, disease free survival (DFS) was more accurately stratified using pre-treatment ctDNA status [HR 4.34 (95% CI 0.93-20.21); P = 0.05] compared to nodal status on PET-CT. In an exploratory subgroup analysis, patients who are node negative but ctDNA positive have inferior DFS [HR 11.71 (95% CI 1.16-118.80) P = 0.04]. In blood samples taken before and following NAT, clearance of ctDNA after NAT was associated with a favourable response to treatment. Furthermore, patients who are ctDNA positive during post-treatment surveillance are at high risk of relapse. CONCLUSIONS: Our study shows that ctDNA has potential to provide additional prognostication over conventional staging investigation such as CT and PET. It may also have clinical utility in the assessment of response to NAT and as a biomarker for the surveillance of recurrent disease.
-
ItemGermline MBD4 deficiency causes a multi-tumor predisposition syndromePalles, C ; West, HD ; Chew, E ; Galavotti, S ; Flensburg, C ; Grolleman, JE ; Jansen, EAM ; Curley, H ; Chegwidden, L ; Arbe-Barnes, EH ; Lander, N ; Truscott, R ; Pagan, J ; Bajel, A ; Sherwood, K ; Martin, L ; Thomas, H ; Georgiou, D ; Fostira, F ; Goldberg, Y ; Adams, DJ ; van der Biezen, SAM ; Christie, M ; Clendenning, M ; Thomas, LE ; Deltas, C ; Dimovski, AJ ; Dymerska, D ; Lubinski, J ; Mahmood, K ; van der Post, RS ; Sanders, M ; Weitz, J ; Taylor, JC ; Turnbull, C ; Vreede, L ; van Wezel, T ; Whalley, C ; Arnedo-Pac, C ; Caravagna, G ; Cross, W ; Chubb, D ; Frangou, A ; Gruber, AJ ; Kinnersley, B ; Noyvert, B ; Church, D ; Graham, T ; Houlston, R ; Lopez-Bigas, N ; Sottoriva, A ; Wedge, D ; Jenkins, MA ; Kuiper, RP ; Roberts, AW ; Cheadle, JP ; Ligtenberg, MJL ; Hoogerbrugge, N ; Koelzer, VH ; Rivas, AD ; Winship, IM ; Ponte, CR ; Buchanan, DD ; Power, DG ; Green, A ; Tomlinson, IPM ; Sampson, JR ; Majewski, IJ ; de Voer, RM (CELL PRESS, 2022-05-05)We report an autosomal recessive, multi-organ tumor predisposition syndrome, caused by bi-allelic loss-of-function germline variants in the base excision repair (BER) gene MBD4. We identified five individuals with bi-allelic MBD4 variants within four families and these individuals had a personal and/or family history of adenomatous colorectal polyposis, acute myeloid leukemia, and uveal melanoma. MBD4 encodes a glycosylase involved in repair of G:T mismatches resulting from deamination of 5'-methylcytosine. The colorectal adenomas from MBD4-deficient individuals showed a mutator phenotype attributable to mutational signature SBS1, consistent with the function of MBD4. MBD4-deficient polyps harbored somatic mutations in similar driver genes to sporadic colorectal tumors, although AMER1 mutations were more common and KRAS mutations less frequent. Our findings expand the role of BER deficiencies in tumor predisposition. Inclusion of MBD4 in genetic testing for polyposis and multi-tumor phenotypes is warranted to improve disease management.
-
ItemClassification of myeloid neoplasms/acute leukemia: Global perspectives and the international consensus classification approach COMMENTArber, DA ; Hasserjian, RP ; Orazi, A ; Mathews, V ; Roberts, AW ; Schiffer, CA ; Roug, AS ; Cazzola, M ; Doehner, H ; Tefferi, A (WILEY, 2022-02-25)